Trials / Unknown
UnknownNCT05132413
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
A Phase 3, Randomized Double-blind, Placebo-controlled, Multicenter Study of SHR-1701 in Combination With Bevacizumab and Chemotherapy in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer With EGFR Mutation After Failure of TKIs
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 561 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after failure of TKIs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab | SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab |
| DRUG | Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin | Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin |
| DRUG | Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin | Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin |
Timeline
- Start date
- 2021-12-30
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2021-11-24
- Last updated
- 2021-11-24
Source: ClinicalTrials.gov record NCT05132413. Inclusion in this directory is not an endorsement.